The relationship between P-gp and CD147 in the regulation of MDR in leukemic cells has not been reported. This study aimed to investigate the correlation between CD147 and P-gp in the regulation of drug resistance in the K562/ADR leukemic cell line. The results showed that drug-resistant K562/ADR cells expressed significantly higher P-gp and CD147 levels than drug-free K562/ADR cells. To determine the regulatory effect of CD147 on P-gp expression, anti-CD147 antibody MEM-M6/6 significantly decreased P-gp and CD147 mRNA and protein levels. This is the first report to show that CD147 mediates MDR in leukemia through the regulation of P-gp expression.
Introduction
Leukemia, a type of blood cancer, originates from abnormal hematopoietic stem cells and results in a high number of abnormal white blood cells. Chemotherapy, using cytotoxic drugs to destroy cancer cells, has been the most effective treatment. However, multidrug resistance (MDR), the ability of cancer cells to survive exposure to many chemotherapeutic drugs, is the major problem in cancer treatment. Recent studies have revealed that overexpression of drug transporter proteins, such as P-glycoprotein (Pgp), is associated with resistance to multiple chemotherapeutic drugs [1, 2] . P-gp is a 170 kDa transmembrane protein encoded by the MDR1 gene. It functions as a pump to remove anticancer drugs from cells, thereby leading to drug resistance. As reported, P-gp is overexpressed in several drug-resistant cancer cell lines [3] [4] [5] . Thus, P-gp might potentially be a key molecule in MDR cancer. However, the regulatory mechanism of this protein was not elucidated. CD147 is a protein in the immunoglobulin superfamily group [6] [7] [8] [9] ; it promotes many properties of cancer cells, including multidrug resistance [10] [11] [12] . A number of studies have shown the high expression level and involvement of CD147 in many MDR cell lines [13, 14] . These studies suggested that CD147 plays an important role in regulating resistance to anticancer drugs. However, the regulatory mechanism of CD147 on the P-gp in leukemic cells remains unclear.
In this study, drug-free K562/ADR cells were established and then used as a drug-resistant phenotype cell control. The CD147 and P-gp demonstrated high expression in drug-resistant K562/ ADR cells more than drug-free K562/ADR cells, in both mRNA and protein levels. In addition, the mechanism through which CD147 regulates P-gp in multidrug-resistant leukemic cells was investigated using monoclonal antibodies (mAb) against CD147, MEM-M6/6. MEM-M6/6 down-regulated the expression of MDR1 mRNA and P-gp in drug-resistant K562/ADR cells. The CD147 was purposed to involve in multidrug resistance through regulation of P-gp expression in leukemia cells.
Materials and methods

Antibodies
This study used the following antibodies: mouse anti-CD147 monoclonal antibody clone MEM-M6/6 (Exbio, Vestec, Czech Republic); mouse anti-P-gp monoclonal antibody (MT PGP1) (Biomedical Technology Research Center, Chiang Mai, Thailand) [15] , mouse anti-γ 4 Technology Research Center) [16] , rabbit anti-CD147 polyclonal antibody (Abcam, Cambridge, UK), rabbit anti-GAPDH polyclonal antibody (Merck Millipore, Billeric, MA, USA), goat anti-rabbit IgG-HRP (Abcam), and rabbit anti-mouse Igs-FITC (Dako, Hamburg, Germany).
Cell lines and culture
The human leukemia cell line, K562/ADR (Adriamycin resistant K562) was purchased from Riken (Riken, Yokohama, Japan) and maintained in RPMI1640 medium (GIBCO™, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS), penicillin, and streptomycin at 37°C in 5% CO 2 . Before the experiment, the drug-resistant K562/ADR was cultured in 0.5, 0.75, and 1 μg/mL of Adriamycin (Sigma, St. Louis, MO, USA) to maintain MDR phenotype. Drug-free K562/ADR was generated by growing K562/ADR in culture medium without Adriamycin for at least 5 months to make them sensitive to Adriamycin.
Antibody treatment
To determine the involvement of the CD147 molecule on the expression and function of P-gp, drug-resistant K562/ADR cells were plated at 2 Â 10 5 cells/well, then co-cultured with anti-CD147
clone MEM-M6/6 (Exbio) at various concentrations (0-5 mg/mL) for 24-48 h. PB1 antibody against γ 4 -globin (hemoglobin Bart's) was used as the isotype matched control (IgG 1 ).
Western blot analysis
Cells were harvested and extracted with RIPA lysis buffer. The total protein concentration was determined using the Folin-Lowry method and 30 μg of total protein were electrophoresed on 10% SDS-PAGE gels. After electrophoresis, the proteins were transferred to polyvinylidene difluoride membranes. The blots were blocked with 5% skim milk-PBS before incubating with 10 μg/mL of mouse monoclonal anti-P-gp antibody (MT-PGP1) (Biomedical Technology Research Center), 1 μg/mL of rabbit polyclonal anti-CD147 antibody (Abcam), or 1 μg/mL of rabbit polyclonal anti-GAPDH antibody (Merck Millipore) for 1 h. Then goat polyclonal anti-rabbit IgG conjugated with HRP (1:20,000 dilution; Abcam) or polyclonal rabbit anti-mouse IgG-HRP (1:5000 dilution; Dako) was added for 2 h. After washing, the signal was detected using Luminata™ forte Western HRP Substrate (Merck Millipore).
Semi-quantitative reverse transcription-PCR
Total RNA was extracted from cells with TRIzol reagent (Life Technologies) according to the manufacturer's instructions. Singlestranded cDNA was synthesized by reverse transcription from 1 μg of total RNA using the RevertAid strand cDNA Synthesis Kit (Thermo Scientific, USA). Then, 1 μg cDNA was amplified by PCR using a DreamTag Green PCR Master Mix (Thermo ScientificTM). The primer sequences are shown in Table 1 . The PCR products were electrophoresed on 1.2% agarose gels, followed by ethidium bromide staining.
Intracellular rhodamine 123 (Rho123) accumulation assay
After treatment, 2 Â 10 5 cells were incubated with Rho123 dye at a final concentration of 10 μM for 90 min. After incubation, the cells were harvested and washed twice with ice-cold PBS, and then resuspended in PBS. The fluorescence intensity of the cells was determined using a FACS Calibur flow cytometer (Becton Dickinson, San Jose, CA, USA).
Statistical analysis
Data were expressed as mean 7SEM. Statistical analysis was performed with SPSS 20.0 software. Statistical significance between two groups was determined by Student's t-test. Results from more than two experimental groups were evaluated by oneway Mann-Whitney U test. A difference was considered statistically significant at p o0.05.
Results
Expression of P-gp and CD147 in drug-resistant and drug-free K562/ADR leukemic cell lines
To investigate the multidrug resistance phenotype of drug-resistant K562/ADR and drug-free K562/ADR cell lines, MTT assay was performed to compare the sensitivity of both leukemia cell lines to Adriamycin drug. Drug-resistant K562/ADR and drug-free K562/ADR cell lines were treated with various concentrations of Adriamycin for 48 h. It was found that Adriamycin was more cytotoxic effect to drug-free K562/ADR than drug-resistant K562/ ADR cells (Fig. 1) . Western blot analysis and semi-quantitative RT-PCR were employed to determine the expression levels of P-gp and CD147 in both drug-resistant K562/ADR and drug-free K562/ADR cells. Representative samples of the immunoblotting results are shown in Fig. 2A . The results showed a higher expression level of P-gp and CD147 proteins in drug-resistant K562/ADR than in drugfree K562/ADR (p o0.05) (Fig. 2B) . Furthermore, the results showed significantly higher expression levels of MDR1 and BSG mRNA in drug-resistant K562/ADR compared to drug-free Table 1 The sequences of primers used to amplify MDR1, BSG, BIRC5 and GAPDH mRNAs [3, 17] .
Gene
Primer sequence K562/ADR (p o0.05), as shown in Fig. 3 . The MDR mRNA, P-gp, and CD147 levels were much higher in drug-resistant K562/ADR than drug-free K562/ADR cells. According to the previous reports, these results confirmed that P-gp and CD147 were involved in the leukemic cell with MDR phenotype.
3.2. MEM-M6/6 mAb inhibits the expression of P-gp and CD147 protein in drug-resistant K562/ADR cell line Because CD147 is involved in cancer multidrug resistance, the CD147 was further determined in the regulation of P-gp. Drugresistant K562/ADR cells were treated with MEM-M6/6 anti-CD147 or PB1 anti-γ 4 globin (isotype matched control) for 48 h, then the expression of P-gp and CD147 proteins was examined by Western blotting. As shown in Fig. 4 , the results demonstrated that MEM-M6/6 antibody treatment significantly decreased the expression of P-gp and CD147 proteins in a dose-dependent manner.
The MEM-M6/6 mAb at 5 μg/mL had no effect on cell viability (data not shown). In contrast, at 5 μg/mL, PB1 anti-γ 4 globin mAb
showed no difference of all tested proteins expression. (Fig. 5 ). In addition, 5 μg/mL MEM-M6/6 antibody significantly decreased MDR1 and BSG mRNA levels (p o0.05). For the isotype matched control, the results showed no difference in the mRNA levels in treated and untreated drug-resistant K562/ ADR cells. These results suggested that triggering CD147 by anti-CD147 mAb MEM-M6/6 decreased the expression of CD147, leading to a decrease of MDR1 expression.
Effects of MEM-M6/6 mAb on P-gp function
To investigate whether MEM-M6/6 mAb affects P-gp function, the intracellular accumulation of Rho123 in the presence or absence of MEM-M6/6 antibody was determined in drug-resistant K562/ADR and drug-free K562/ADR cells. As shown in Fig. 6 , the relative mean fluorescence intensity (MFI) in drug-resistant K562/ ADR cells was significantly lower than drug-free K562/ADR cells (p o0.05). For drug-resistant K562/ADR cells, there was no significant difference in Rho123 intracellular accumulation in MEM-M6/6 antibody treatment compared to untreated cells. The accumulation of Rho123 did not alter in PB1 anti-γ 4 globin mAb treated cells. However, the MFI of Rho123 was significantly higher in curcumin (MDR modulator) treated K562/ADR cells than untreated cells (p o0.05).
Discussion
There are several mechanisms of MDR, including decreased MEM-M6/6 concentration (µg/ml) µ Fig. 4 . Effect of MEM-M6/6 anti-CD147 on P-gp (A) and CD147 (B) protein expression in drug-resistant K562/ADR cell line. The protein levels after treating drug-resistant K562/ADR cell with (1) 0 μg/mL MEM-M6/6, (2) 0.625 μg/mL, (3) 1.25 μg/mL, (4) 2.5 μg/mL, and (5) 5 μg/mL for 48 h were determined by Western blotting. The bands were quantified using a scan densitometer. The protein levels were normalized to the loading control GAPDH. Data are presented as mean7 SEM of three independent experiments; drug uptake, reduced intracellular drug concentration by efflux pumps, or altered cell-cycle checkpoints [18] [19] [20] . Among these, overexpression of P-gp, ATP-binding cassette (ABC) drug transporters, is an important mechanism [1, 2] . P-gp is a transmembrane glycoprotein that is widely expressed in many human cancers [21] . Levels of P-gp have been correlated with drug resistance in several different cancers [1, 2, 20, 22] . Therefore, understanding MDR is important to help patients for reducing or preventing chemotherapy resistance.
CD147 is a type I transmembrane glycoprotein of the immunoglobulin superfamily. CD147 has been reported to regulate the expression of P-gp and affect apoptosis in cancer cells with MDR phenotype [10, 13, 14] . In the present study, drug-free K562/ ADR was first established by culturing K562/ADR in medium without Adriamycin for at least five months. Then Adriamycin drug sensitivities of both drug-resistant and drug-free K562/ADR cells were determined and compared by MTT assay. The results showed that Adriamycin was more cytotoxic in drug-free K562/ ADR cells than drug-resistant K562/ADR cells. Moreover, the drugresistant K562/ADR cell line presented high expression levels of P-gp and CD147, suggesting that both proteins are associated with the MDR phenotype in leukemic cells. This finding is in line with previous studies that have demonstrated high levels of mRNA and protein expression of MDR1 and CD147 in MDR cancer cell lines [13] . Recent studies have revealed CD147 is responsible for the altered multidrug resistance to P-gp substrate drugs [14] . Up-regulation of MDR1 at both transcription and expression levels was found in CD147-transfected MCF7 breast cancer cells, which promotes multidrug resistance to P-gp substrate drugs. In addition, silencing of CD147 led to increase chemosensitivity in MDR cancer cell lines [23, 24] . As previously mentioned, the linkage exists among CD147 and P-gp in leukemia with MDR were further investigated. Drug-resistant K562/ADR cells were co-cultured with MEM-M6/6 anti-CD147 mAb, and then P-gp and CD147 expression were determined by Western blotting and semi-quantitative RT-PCR. The MEM-M6/6 antibody decreased the expression of P-gp and CD147 proteins and mRNA levels, suggesting the regulation of P-gp expression by CD147 molecule in the association of multidrug resistant phenotype in K562/ADR cells. As previously reported, the CD147 molecule contains different bioactive domains responsible for cell functions [25] . Therefore, activation of bioactive domains, by specific mAbs or its natural ligands, induces different cellular responses [25] . MEM-M6/6 was reported as a CD147 mAb, which recognized the membrane-proximal domain of the CD147 molecule [26] . These results suggest that the membrane-proximal domain of the CD147 molecule may be a particular domain that is responsible for the regulation of multidrug resistance. Furthermore, triggering CD147 with MEM-M6/6 decreased the expression of CD147, which in turn down-regulated P-gp expression.
The further investigation was performed by using MEM-M6/6 antibody to observe the linkage exits between CD147 and P-gp activity by intracellular Rho123 accumulation. MEM-M6/6 treatment did not alter Rho123 accumulation in drug-resistant K562/ ADR cells. In contrast, the fluorescence intensity of Rho123 was significantly high in K562/ADR cells treated with curcumin, which is a P-gp modulator used as a positive control [27] . These results indicated that the decreased expression of CD147 by anti-CD147 MEM-M6/6 did not affect the P-gp function. It has been suggested that CD147 is involved in leukemia drug resistance by down-regulating Pgp, but not related to its drug efflux function [28, 29] .
Triggering of CD147 by MEM-M6/6 anti-CD147 mAb decreased expression of CD147 and caused downregulation of P-gp, but had no effect on P-gp function. Most strategies to reverse MDR phenotype in cancer cells have used drug efflux modulators. Moreover, to avoid MDR could be downregulated the expression of the target gene that involved in MDR such as MDR1 gene. Therefore, we propose regulating CD147 expression as a new strategy to overcome MDR. In summary, the CD147 involved the MDR phenotype of leukemic cells by regulating P-gp expression.
